Filing Details
- Accession Number:
- 0000880771-11-000001
- Form Type:
- 4
- Zero Holdings:
- No
- Publication Time:
- 2011-05-16 14:58:14
- Reporting Period:
- 2011-05-12
- Filing Date:
- 2011-05-16
- Accepted Time:
- 2011-05-16 14:58:14
- SEC Url:
- Form 4 Filing
Issuer
Cik | Name | Symbol | Sector (SIC) | IRS No |
---|---|---|---|---|
880771 | Sciclone Pharmaceuticals Inc | SCLN | Pharmaceutical Preparations (2834) | 943116852 |
Insiders
Cik | Name | Reported Address | Insider Title | Director | Officer | Large Shareholder | Other |
---|---|---|---|---|---|---|---|
1363213 | Friedhelm Blobel | 950 Tower Lane, Suite 900 Foster City CA 94404 | President & Ceo | Yes | Yes | No | No |
Reported Non-Derivative Transactions
Sec. Name | Acquisiton - Disposition | Date | Amount | Price | Remaning Holdings | Equity Swap Involved | Form Type | Code | Nature of Ownership | Explanation |
---|---|---|---|---|---|---|---|---|---|---|
Common Stock | Acquisiton | 2010-11-30 | 1,000 | $2.15 | 29,000 | No | 4 | P | Direct | |
Common Stock | Acquisiton | 2011-02-28 | 1,000 | $3.29 | 30,000 | No | 4 | P | Direct |
Equity Swap Involved | Form Type | Code | Nature of Ownership | Explanation |
---|---|---|---|---|
No | 4 | P | Direct | |
No | 4 | P | Direct |
Reported Derivative Transactions
Sec. Name | Sec. Type | Acquisiton - Disposition | Date | Amount | Price | Amount - 2 | Price - 2 |
---|---|---|---|---|---|---|---|
Common Stock | Common Stock | Acquisiton | 2011-05-12 | 150,000 | $5.13 | 150,000 | $5.13 |
Remaning Holdings | Exercise Date | Expiration Date | Equity Swap Involved | Transaction Form Type | Transaction Code | Nature of Ownership |
---|---|---|---|---|---|---|
150,000 | 2021-05-12 | No | 4 | A | Direct |
Footnotes
- Purchased under the Issuer's Employee Stock Purchase Plan on November 30, 2010.
- Purchased under the Issuer's Employee Stock Purchase Plan on February 28, 2011.
- Granted under the Issuer's 2005 Equity Incentive Plan.
- 25% of such shares vest April 5, 2012 and 2.0833% vests each month thereafter, provided that Reporting Person continues to be employed by the Issuer.